Cookie Policy

We've put some small files called essential cookies on your device to help our site work on your browser.
We also use analytical cookies to help up improve our website by collecting and reporting information on it's usage.

You can read more above this on our Privacy Policy page.

I'm ok with analytical cookies Do not use analytics cookies

Our Strategy and Values

The commercial strategy of the Group has a number of key elements:

Our Strategic Goals - As set out in our 2020 Annual Report

1

Launch Accrufer® in the US
– Preparations for launch are underway

2

Continue paediatric Phase III study
– Main paediatric study to start summer 2021

3

Continue to out-license commericalisation of Feraccru® in other markets
– Discussions with potential partners in several markets are underway

4

Re-start development of PT20
– PT20 formulation development to start in H1 2021

Our Values

  • Patient centric: The patients our therapies treat are at the heart of why we do it
  • Ethical: Always professional with the highest of standards
  • Product focused: We have a great track record of identifying value and are always looking for more
  • Freedom to operate: It is “our” Company and we avoid hierarchy, we challenge to succeed
  • Relationships: Strong and human… everyone is valuable
  • Continuously develop: We only want people who are committed, effective and determined to succeed